Cotadutide | CAS# 1686108-82-6 | dual receptor agonist

MedKoo Cat#: 413301 | Name: Cotadutide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cotadutide is a dual receptor agonist that modifies the activity of glucagon and glucagon-like peptide-1 (GLP-1).

Chemical Structure

Cotadutide

CAS#1686108-82-6 (free base)

Theoretical Analysis

MedKoo Cat#: 413301

Name: Cotadutide

CAS#: 1686108-82-6 (free base)

Chemical Formula: C102H155N23O39

Exact Mass: 2326.0853

Molecular Weight: 2327.48

Elemental Analysis: C, 52.64; H, 6.71; N, 13.84; O, 26.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

Cotadutide (acetate) 1686108-82-6 (free base)

Synonym

Cotadutide; MEDI0382; MEDI 0382; MEDI-0382

IUPAC/Chemical Name

Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl

InChi Key

PZYXJUYKNTXGFG-YKFZEJPPSA-N

InChi Code

InChI=1S/C102H155N23O39/c1-6-7-8-9-10-11-12-13-14-15-19-25-77(135)110-65(102(163)164)31-35-76(134)106-38-21-20-24-61(89(150)121-72(49-127)98(159)114-64(33-37-80(139)140)90(151)116-67(41-57-26-28-59(132)29-27-57)92(153)115-66(39-53(2)3)91(152)117-70(44-82(143)144)94(155)122-73(50-128)97(158)113-63(32-36-79(137)138)88(149)108-47-83(145)146)111-93(154)69(43-81(141)142)118-99(160)74(51-129)123-101(162)85(55(5)131)125-95(156)68(40-56-22-17-16-18-23-56)119-100(161)84(54(4)130)124-78(136)46-107-87(148)62(30-34-75(104)133)112-96(157)71(48-126)120-86(147)60(103)42-58-45-105-52-109-58/h16-18,22-23,26-29,45,52-55,60-74,84-85,126-132H,6-15,19-21,24-25,30-44,46-51,103H2,1-5H3,(H2,104,133)(H,105,109)(H,106,134)(H,107,148)(H,108,149)(H,110,135)(H,111,154)(H,112,157)(H,113,158)(H,114,159)(H,115,153)(H,116,151)(H,117,152)(H,118,160)(H,119,161)(H,120,147)(H,121,150)(H,122,155)(H,123,162)(H,124,136)(H,125,156)(H,137,138)(H,139,140)(H,141,142)(H,143,144)(H,145,146)(H,163,164)/t54-,55-,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,84+,85+/m1/s1

SMILES Code

O=C(O)CNC([C@H](CCC(O)=O)NC([C@H](CO)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CCC(O)=O)NC([C@H](CO)NC([C@H](CCCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCC)=O)=O)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC2=CC=CC=C2)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](CC3=CNC=N3)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 2,327.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 May;2(5):413-431. doi: 10.1038/s42255-020-0209-6. Epub 2020 May 21. PMID: 32478287; PMCID: PMC7258337. 2: Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz047. doi: 10.1210/clinem/dgz047. PMID: 31608926. 3: Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. doi: 10.1111/dom.12735. Epub 2016 Aug 15. PMID: 27377054; PMCID: PMC5129521. 4: Yang PY, Zou H, Amso Z, Lee C, Huang D, Woods AK, Nguyen-Tran VTB, Schultz PG, Shen W. New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. Bioconjug Chem. 2020 Apr 15;31(4):1167-1176. doi: 10.1021/acs.bioconjchem.0c00093. Epub 2020 Apr 3. PMID: 32243137. 5: Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. PMID: 29945727. 6: Lainé AL, Houvenagel S, Broo A, Jones I, Goodman J, Corkill D, Rose J, Coward S, Sandinge AS, Petrone M, Jermutus L, Santos ALGD. Developing an injectable co- formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic properties. Int J Pharm. 2020 Feb 25;576:119019. doi: 10.1016/j.ijpharm.2020.119019. Epub 2020 Jan 3. PMID: 31911116. 7: Rayner CK, Horowitz M. Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one? Lancet. 2018 Jun 30;391(10140):2577-2578. doi: 10.1016/S0140-6736(18)30936-X. Epub 2018 Jun 23. PMID: 29945728. 8: Darbalaei S, Yuliantie E, Dai A, Chang R, Zhao P, Yang D, Wang MW, Sexton PM, Wootten D. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochem Pharmacol. 2020 Oct;180:114150. doi: 10.1016/j.bcp.2020.114150. Epub 2020 Jul 17. PMID: 32682761. 9: Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br J Clin Pharmacol. 2018 Oct;84(10):2325-2335. doi: 10.1111/bcp.13688. Epub 2018 Aug 7. PMID: 29926478; PMCID: PMC6138475.